We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Looking for the value option

4 January 2007 By John Foley

The Dutch conglomerate is pushing on with a float of the pharma business. That means investors have to take a punt on the drug pipeline. But the operation s health has deteriorated. At the right price, a bid could prove the more attractive option for shareholders.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)